Drug Trial Radar · NCT05232071
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Jun 29, 2022
Primary completion
May 8, 2024
Study completion Jun 4, 2024
Sponsor
- Lead sponsor
- Inventiva PharmaIndustry
- Sponsor type
- Industry
- First posted
- Feb 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
Conditions
- NASH - Nonalcoholic Steatohepatitis
- Diabetes Mellitus, Type 2
Interventions
LanifibranorDrug
800 mg
PlaceboDrug
Placebo to match
EmpagliflozinDrug
10 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change in HbA1cTime frame: From Baseline to Week 24
Locations
42 sites in 5 countries. Site status is shown where the registry gives one.
Birmingham Digestive Health Research
Homewood, Alabama
Institute for Liver Health dba Arizona Liver Health
Chandler, Arizona
ARcare Center for Clinical Research
Conway, Arkansas
ARcare Center for Clinical Research
Little Rock, Arkansas
Cure Clinical Research, LLC
Fountain Valley, California
Velocity Clinical Research
Gardena, California
National Research Institute
Huntington Park, California
Cadena Care Institute, LLC
Poway, California
Florida Research Institute
Lakewood Rch, Florida
Galenus Group
Lehigh Acres, Florida
Prolive Medical Research
Miami, Florida
Indiana University School of Medicine
Indianapolis, Indiana
Digestive Health Research of Southern California
South Bend, Indiana
Tandem Clinical Research - New Orleans Area Site
Marrero, Louisiana
Harvard Medical School
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
AIG Digestive Disease Research
Florham Park, New Jersey
Digestive Health Research
Hermitage, Tennessee
Accelemed Research Institute
Austin, Texas
Dallas Diabetes Research Center
Dallas, Texas
American Research Corporation
San Antonio, Texas
Diabetes & Glandular Disease Clinic, P.A.
San Antonio, Texas
Impact Research Institute
Waco, Texas
Digestive Health Research of North Texas
Wichita Falls, Texas
University of Virginia
Charlottesville, Virginia
Central Virginia VA Healthcare System
Richmond, Virginia
CUB Erasme Hospital
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
AZ Maria Middelares
Ghent, Belgium
UZ GENT
Ghent, Belgium
CHU Angers_Service d'hepatogastro-enterologie
Angers, France
CHU Limoges
Limoges, France
Hopital Saint Antoine
Paris, France
CHU Bordeaux
Pessac, France
Chu Rangueil
Toulouse, France
HGE CHRU Nancy
Vandœuvre-lès-Nancy, France
Amsterdam UMC
Amsterdam, Netherlands
Hull University Teaching Hospital
Hull, United Kingdom
King's College Hospital
London, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.